{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T11:38:00Z","timestamp":1775475480112,"version":"3.50.1"},"reference-count":44,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mem. Inst. Oswaldo Cruz"],"DOI":"10.1590\/0074-02760210386","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T13:42:56Z","timestamp":1647438176000},"source":"Crossref","is-referenced-by-count":3,"title":["Repositioning drug strategy against Trypanosoma cruzi: lessons learned from HIV aspartyl peptidase inhibitors"],"prefix":"10.1590","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3715-1967","authenticated-orcid":false,"given":"Leandro Stefano","family":"Sangenito","sequence":"first","affiliation":[{"name":"Universidade Federal do Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia Masini","family":"d\u2019Avila-Levy","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta Helena","family":"Branquinha","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 Luis Souza dos","family":"Santos","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro, Brazil; Universidade Federal do Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2022]]},"reference":[{"key":"ref1","year":"2021"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fpubh.2019.00166","article-title":"Chagas disease from discovery to a worldwide health problem","volume":"2","author":"Lidani KCF","year":"2019","journal-title":"Front Public Health"},{"key":"ref3","first-page":"75","article-title":"Investing to overcome the global impact of neglected tropical diseases third WHO report on neglected diseases","volume":"2","year":"2015","journal-title":"Library Cataloguing-in-Publication Data"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1590\/0037-8682-0433-2016","article-title":"Chagas disease review of needs, neglect, and obstacles to treatment access in Latin America","volume":"50","author":"Pinheiro E","year":"2017","journal-title":"Rev Soc Bras Med Trop"},{"key":"ref5","series-title":"Chagas disease","year":"2021"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1473-3099(13)70002-1","article-title":"Global economic burden of Chagas disease a computational simulation model","volume":"13","author":"Lee BY","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"20","key":"ref7","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.2174\/1568026616666160413124902","article-title":"Advances and progress in Chagas disease drug discovery","volume":"16","author":"Ferreira LG","year":"2016","journal-title":"Curr Top Med Chem"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/tropicalmed5020088","article-title":"Funding for Chagas disease a 10-year (2009-2018) survey","volume":"5","author":"Sangenito LS","year":"2020","journal-title":"Trop Med Infect Dis"},{"key":"ref9","article-title":"Critical analysis of Chagas disease treatment in different countries","volume":"116","author":"Mendes FSNS","year":"2021","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/156802661903190328155136","article-title":"Leishmaniasis and Chagas disease - neglected tropical diseases treatment updates","volume":"19","author":"Sangenito LS","year":"2019","journal-title":"Curr Top Med Chem"},{"key":"ref11","article-title":"Drug repositioning: the business case and current strategies to repurpose shelved candidates and marketed drugs","author":"Arrowsmith J","year":"2012","journal-title":"John Wiley Sons"},{"issue":"7607","key":"ref12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks","volume":"534","author":"Nosengo N","year":"2016","journal-title":"Nature"},{"issue":"19","key":"ref13","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2174\/1568026616666160216154309","article-title":"Neglected tropical protozoan diseases drug repositioning as a rational option","volume":"16","author":"Sbaraglin ML","year":"2016","journal-title":"Curr Top Med Chem"},{"issue":"10","key":"ref14","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.drudis.2016.06.021","article-title":"Drug repositioning approaches to parasitic diseases a medicinal chemistry perspective","volume":"21","author":"Ferreira LG","year":"2016","journal-title":"Drug Discov Today"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.3390\/ph11020057","article-title":"Changing trends in computational drug repositioning","volume":"11","author":"Yella JK","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acs.jmedchem.5b00497","article-title":"Anti-HIV drug discovery and development current innovations and future trends","volume":"59","author":"Zhan P","year":"2016","journal-title":"J Med Chem"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1021\/ar8000519","article-title":"Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus","volume":"41","author":"Tsantrizos YS","year":"2008","journal-title":"Chem Res"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.4081\/idr.2013.s1.e2","article-title":"Recent developments in HIV treatment and their dissemination in poor countries","volume":"5","author":"Ebrahim O","year":"2013","journal-title":"Infect Dis Rep"},{"issue":"26","key":"ref19","doi-asserted-by":"crossref","DOI":"10.2174\/092986707782360141","article-title":"Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors","volume":"14","author":"Mastrolorenzo A","year":"2007","journal-title":"Curr Med Chem"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/1874104501105010040","article-title":"HIV protease inhibitors effect on the opportunistic protozoan parasites","volume":"5","author":"Alfonso Y","year":"2011","journal-title":"Open Med Chem J"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2174\/1568026616666161025161153","article-title":"The widespread anti-protozoal action of HIV aspartic peptidase inhibitors focus on Plasmodium spp., Leishmania spp. and Trypanosoma cruzi","volume":"17","author":"Santos ALS","year":"2017","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00005792-200101000-00006","article-title":"Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non HIV infected patients A comparative study","volume":"80","author":"Pintado V","year":"2001","journal-title":"Medicine"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1590\/S0037-86822006000100018","article-title":"Prolonged survival and immune reconstitution after chagasic meningoencephalitis in a patient with acquired immunodeficiency syndrome","volume":"39","author":"Corti M","year":"2006","journal-title":"Rev Soc Bras Med Trop"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/QCO.0000000000000023","article-title":"Management of Trypanosoma cruzi coinfection in HIV-positive individuals outside endemic areas","volume":"27","author":"P\u00e9rez-Molina JA","year":"2014","journal-title":"Curr Opin Infect Dis"},{"key":"ref25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113957","article-title":"Decoding the anti-Trypanosoma cruzi action of HIV peptidase inhibitors using epimastigotes as a model","author":"Sangenito LS","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ijantimicag.2016.06.024","article-title":"HIV aspartic peptidase inhibitors are effective drugs against the trypomastigote form of the human pathogen Trypanosoma cruzi","volume":"48","author":"Sangenito LS","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"5733","key":"ref27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.1112631","article-title":"The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas' disease","volume":"309","author":"El-Sayed NM","year":"2005","journal-title":"Science"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.exppara.2009.02.005","article-title":"Trypanosoma cruzi isolation and characterization of aspartyl proteases","volume":"122","author":"Pinho RT","year":"2009","journal-title":"Exp Parasitol"},{"issue":"11","key":"ref29","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.3390\/biom10111564","article-title":"Trypanosoma cruzi presenilin-like transmembrane aspartyl protease characterization and cellular localization","volume":"10","author":"Lechuga GC","year":"2020","journal-title":"Biomolecules"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1186\/s13104-018-3927-z","article-title":"Docking simulation between HIV peptidase inhibitors and Trypanosoma cruzi aspartyl peptidase","volume":"11","author":"Castilho VVS","year":"2018","journal-title":"BMC Res Notes"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"215223","DOI":"10.1177\/135965350501000203","article-title":"The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function","volume":"10","author":"Piccinini M","year":"2005","journal-title":"Antivir Ther"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1124\/jpet.106.111849","article-title":"Inhibition of human preadipocyte proteasomal activity by HIV protease inhibitors or specific inhibitor lactacystin leads to a defect in adipogenesis, which involves matrix metalloproteinase-9","volume":"320","author":"De Barros S","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bbadis.2013.11.019","article-title":"HIV protease inhibitors and onset of cardiovascular diseases a central role for oxidative stress and dysregulation of the ubiquitin-proteasome system","volume":"1842","author":"Reyskens KM","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ejmech.2015.01.065","article-title":"Computer guided drug repurposing identification of trypanocidal activity of lofazimine, benidipine and saquinavir","volume":"93","author":"Bellera CL","year":"2015","journal-title":"Eur J Med Chem"},{"issue":"36","key":"ref35","doi-asserted-by":"crossref","first-page":"6590","DOI":"10.2174\/0929867326666190610152934","article-title":"Repositioning of HIV aspartyl peptidase inhibitors for combating the neglected human pathogen Trypanosoma cruzi","volume":"26","author":"Sangenito LS","year":"2019","journal-title":"Curr Med Chem"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijantimicag.2018.03.021","article-title":"Primary evidences of the mechanisms of action of HIV aspartyl peptidase inhibitors on Trypanosoma cruzi trypomastigote forms","volume":"52","author":"Sangenito LS","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00436-006-0250-8","article-title":"Ultrastructural analysis of edelfosine-treated trypomastigotes and amastigotes of Trypanosoma cruzi","volume":"100","author":"Santa-Rita RM","year":"2006","journal-title":"Parasitol Res"},{"issue":"6","key":"ref38","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1590\/0074-0276140096","article-title":"JVG9, a benzimidazole derivative, alters the surface and cytoskeleton of Trypanosoma cruzi bloodstream trypomastigotes","volume":"109","author":"D\u00edaz-Chiguer DL","year":"2014","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"1","key":"ref39","first-page":"49","article-title":"Dyslipidemia related to antiretroviral therapy","volume":"13","author":"Estrada V","year":"2011","journal-title":"AIDS Rev"},{"issue":"2","key":"ref40","article-title":"Different cell death pathways induced by drugs in Trypanosoma cruzi: an ultrastructural study","volume":"40","author":"Menna-Barreto RF","journal-title":"Micron"},{"issue":"2","key":"ref41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4161\/auto.7.2.13310","article-title":"Autophagy in protists","volume":"7","author":"Duszenko M","year":"2011","journal-title":"Autophagy"},{"issue":"6","key":"ref42","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ijantimicag.2016.09.017","article-title":"Nelfinavir and lopinavir impair Trypanosoma cruzi trypomastigote infection in mammalian host cells and show anti-amastigote activity","volume":"48","author":"Sangenito LS","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"ref43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2174\/1570162043351129","article-title":"Improving HIV infection management using antiretroviral plasma drug levels monitoring a clinician's point of view","volume":"2","author":"Clevenbergh P","year":"2004","journal-title":"Curr HIV Res"},{"issue":"5","key":"ref44","first-page":"657","article-title":"Determination of lopinavir and ritonavir in blood plasma, seminal plasma, saliva and plasma ultra-filtrate by liquid chromatography\/tandem mass spectrometry detection Rapid Commun Mass","volume":"22","author":"Estrela RC","year":"2008","journal-title":"Spectrom"}],"container-title":["Mem\u00f3rias do Instituto Oswaldo Cruz"],"original-title":[],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T08:25:38Z","timestamp":1674980738000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0074-02762022000100855&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":44,"alternative-id":["S0074-02762022000100855"],"URL":"https:\/\/doi.org\/10.1590\/0074-02760210386","relation":{},"ISSN":["1678-8060","0074-0276"],"issn-type":[{"value":"1678-8060","type":"electronic"},{"value":"0074-0276","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"e210386"}}